|
2017 Journal Article Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisKalincik, Tomas, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut and MSBase Study Group (2017). Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 24 (12), 1352458517728812-1626. doi: 10.1177/1352458517728812 |
|
2017 Journal Article Incidence and prevalence of NMOSD in Australia and New ZealandBukhari, Wajih, Prain, Kerri M., Waters, Patrick, Woodhall, Mark, O'Gorman, Cullen M., Clarke, Laura, Silvestrini, Roger A., Bundell, Christine S., Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce J., Brown, Matthew, Brownlee, Wallace J., Butzkueven, Helmut, Carroll, William M., Chen, Celia, Coulthard, Alan, Dale, Russell C., Das, Chandi, Dear, Keith, Fabis-Pedrini, Marzena J., Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew P. D. ... Broadley, Simon A. (2017). Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology Neurosurgery and Psychiatry, 88 (8), 632-638. doi: 10.1136/jnnp-2016-314839 |
|
2017 Journal Article Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventionsNgo, Shyuan T., Mi, Jia D., Henderson, Robert D., McCombe, Pamela A. and Steyn, Frederik J. (2017). Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degenerative Neurological and Neuromuscular Disease, 7, 95-108. doi: 10.2147/DNND.S120607 |
|
2017 Journal Article Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohortGarton, Fleur C., Benyamin, Beben, Zhao, Qiongyi, Liu, Zhijun, Gratten, Jacob, Henders, Anjali K., Zhang, Zong-Hong, Edson, Janette, Furlong, Sarah, Morgan, Sarah, Heggie, Susan, Thorpe, Kathryn, Pfluger, Casey, Mather, Karen A., Sachdev, Perminder S., McRae, Allan F., Robinson, Matthew R., Shah, Sonia, Visscher, Peter M., Mangelsdorf, Marie, Henderson, Robert D., Wray, Naomi R. and McCombe, Pamela A. (2017). Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort. Molecular Genetics and Genomic Medicine, 5 (4), 418-428. doi: 10.1002/mgg3.302 |
|
2017 Journal Article Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free massIoannides, Z. A., Steyn, F. J., Henderson, R. D., McCombe, P. A. and Ngo, S. T. (2017). Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free mass. Cogent Medicine, 4 (1), 1343000. doi: 10.1080/2331205X.2017.1343000 |
|
2017 Journal Article Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneityMcCombe, P. A., Wray, N. R. and Henderson, R. D. (2017). Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. Expert Review of Neurotherapeutics, 17 (6), 561-577. doi: 10.1080/14737175.2017.1273772 |
|
2017 Journal Article Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survivalXu, Zhouwei, Alruwaili, Ashwag Rafea S., Henderson, Robert David and McCombe, Pamela Ann (2017). Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. Journal of the Neurological Sciences, 376, 16-23. doi: 10.1016/j.jns.2017.02.061 |
|
2017 Conference Publication Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-upOreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Steingo, Brian, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Vermersch, Patrick and on behalf of the CARE-MS I and CAMMS03409 Investigators (2017). Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up. AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.p5.360 |
|
2017 Conference Publication Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I)Singer, Barry, Coles, Alasdair J., Boyko, Alexey N., Cohen, Jeffrey A., De Seze, Jérôme, Fox, Edward J., Havrdova, Eva, Hartung, Hans-Peter, Inshasi, Jihad Said, McCombe, Pamela, Selmaj, Krzysztof W., Vermersch, Patrick, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio and Montalban, Xavier (2017). Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I). AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.s24.005 |
|
2017 Journal Article Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyKalincik, Tomas, Brown, J. William L., Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M., Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent ... Grp, MSBase Study (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, 16 (4), 271-281. doi: 10.1016/S1474-4422(17)30007-8 |
|
2017 Journal Article Anthropometric measures are not accurate predictors of fat mass in ALSIoannides, Zara A., Steyn, Frederik J., Henderson, Robert D., Mccombe, Pamela A. and Ngo, Shyuan T. (2017). Anthropometric measures are not accurate predictors of fat mass in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18 (7-8), 486-491. doi: 10.1080/21678421.2017.1317811 |
|
2017 Journal Article Assessment of motor units in neuromuscular diseaseHenderson, Robert D. and McCombe, Pamela A. (2017). Assessment of motor units in neuromuscular disease. Neurotherapeutics, 14 (1), 69-77. doi: 10.1007/s13311-016-0473-z |
|
2017 Conference Publication The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body compositionIoannides, Zara A., Steyn, Frederik J., Henderson, Robert D., McCombe, Pamela A. and Ngo, Shyuan T. (2017). The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body composition. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2017-316074.35 |
|
2017 Conference Publication Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosisKalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Solaro, C., Grand'Maison, F., Hupperts, R., Prevost, J., Sola, P., Ferraro, D., Terzi, M., Butler, E., Slee, M., Kermode, A., Fabis-Pedrini, M., McCombe, P., Barnett, M., Shaw, C., Hodgkinson, S. and Butzkueven, H. (2017). Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406 |
|
2017 Conference Publication Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registrySpelman, T., Schulz, M., Arora, B., Chung, E., Juneja, P., Walker, R., Verhaeghe, S., Butzkueven, H., Hodgkinson, S., Lechner-Scott, J., McCombe, P., Slee, M., Butler, E., Barnett, M., Skibina, O., Vucic, S., Macdonell, R., Shuey, N., Taylor, B. and Broadley, S. (2017). Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. |
|
2017 Conference Publication Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal studyKalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand'Maison, F., Boz, C., Trojano, M., Van Wijmeersch, B., Pucci, E., Granella, F., Turkoglu, R., Sola, P., Ferraro, D., McCombe, P., Solaro, C., Van Pesch, V., Ozakbas, S., Slee, M. ... Butzkueven, H. (2017). Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404 |
|
2017 Conference Publication Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control ParticipantsSteyn, Frederik J., Restuadi, Restuadi, Ioannides, Zara, Ngo, Shyuan T., McRae, Allan, Wray, Naomi R., Henderson, Robert and McCombe, Pamela (2017). Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: BMJ. doi: 10.1136/jnnp-2017-316074.81 |
|
2017 Conference Publication Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study)Coles, A. J., Boyko, A. N., De Seze, J., Hartung, H-P., Havrdova, E., Inshasi, J. S., McCombe, P., Montalban, X., Pozzilli, C., Selmaj, K. W., Vermersch, P., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Van Wijmeersch, B. (2017). Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406 |
|
2017 Conference Publication The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosisBrown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Prat, A., Girard, M., Hupperts, R., Van Pesch, V., Ferraro, D., Alroughani, R., Bergamaschi, R., Pucci, E., Iuliano, G., Lechner-Scott, J., Spelman, T., Jokubaitis, V., Ramo-Tello, C., Spitaleri, D., Granella, F., Solaro, C., Ampapa, R., Deri, N., McCombe, P., Petersen, T., Van Wijmeersch, B., Prevost, J., Sanchez-Menoyo, J. L. ... Robsertson, N. (2017). The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283 |
|
2017 Conference Publication Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple SclerosisMerkel, Bernd, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pamela, Slee, Mark, Vucic, Steve, Skibina, Olga, Barnett, Michael, Hodgkinson, Suzanne, Butzkueven, Helmut and Kalincik, Tomas (2017). Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.16 |
